An observational study in Recurrent Pregnancy Loss Without Current Pregnancy, sponsored by Bagcilar Training and Research Hospital. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-08-07.
Sponsored by Bagcilar Training and Research Hospital · Observational
The aim of this study is determine vascular endothelial growth factor levels and angiogenesis/vascularity from hysteroscopic endometrial biopsies which taken from patients who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels will be measured by immunohistochemical staining methods due to office hysteroscopic endometrial biopsy after the menstruation at follicular phase of menstrual cycle.
This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.
Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.
320 studies on the registry are indexed under Abortion, Spontaneous; 53 are open to participants now.
This study's enrollment of 30 is below the median of 200 across 140 observational studies indexed under Abortion, Spontaneous.
Browse Abortion, Spontaneous studies →Bagcilar Training and Research Hospital is the lead sponsor of 54 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The patients with Recurrent Pregnancy Loss
Exclusion Criteria:
VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
Patients with Abnormal Uterine Bleeding
The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss
Time frame: 3 months
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bagcilar Training and Research Hospital